Women with primary breast cancer diagnosed at an advanced stage are at increased risk for the development of contralateral breast cancer (CBC), according to the results of a population-based study conducted in Sweden.
In a new study, women who initiated hormone replacement therapy soon after beginning menopause and who continued treatment for 10 years had significantly reduced risk of myocardial infarction, heart failure, or death with no increased risk of cancer, venous thromboembolism, or stroke.
The FDA has approved a new ultrasound device to detect breast cancer in women with dense breasts. It will be used in conjunction with standard mammography in asymptomatic women with a negative mammogram.
In patients with heavily pretreated HER2-positive metastatic breast cancer, combination treatment with lapatinib and trastuzumab was associated with a median survival benefit of 4.5 months, according to the final results of a phase III study.
In a re-analysis of the WHI study 2002, the risks of HRT where misrepresented by the media and not corrected by those affiliated with the research.
In a highly critical re-analysis of the Women’s Health Initiative (WHI) study of 2002, the results of which prompted safety fears about hormone replacement therapy (HRT) significantly increasing the risk of breast cancer, it was concluded that the weight of evidence supports benefits over risks for use of HRT in women with severe symptoms of menopause or other conditions.
The findings of several recent studies involving breast cancer is lending further evidence to the idea that genetics and genomics will soon be the primary focus of diagnosing and treating cancer.
The benefits and risks of breast cancer screening have often been debated by the clinical and epidemiological realms, with key arguments centering around overdiagnosis.
The association between breast cancer and cadmium, a heavy metal that can be found in food, cosmetics, water, and air, has been explored in several new studies with varied findings.
Fatigue, which can plague patients’ years after cancer treatment has ended, may be the result of inflammation. Now, a new study published in the Journal of Clinical Oncology has found that omega-3 may help reduce fatigue associated with inflammation in these patients.